Mobile-health Network Solutions H1 2024 Revenue $6.6M Up From $3M YoY; Expanded Its Headcount And Expenses To Meet Increased Operational Demand And Explore New Market Opportunities, Resulting In An Increase In Net Loss Of $171,634; Cash And Cash...
Mobile-health Network Solutions H1 2024 Revenue $6.6M Up From $3M YoY; Expanded Its Headcount And Expenses To Meet Increased Operational Demand And Explore New Market Opportunities, Resulting In An Increase In Net Loss Of $171,634; Cash And Cash...
Mobile-health Network Solutions H1 2024 Revenue $6.6M Up From $3M YoY; Expanded Its Headcount And Expenses To Meet Increased Operational Demand And Explore New Market Opportunities, Resulting In An Increase In Net Loss Of $171,634; Cash And Cash Equivalents At December 31, 2023 Was ~$2.5M
移动健康网络解决方案2024年上半年收入为660万美元，高于同比300万美元；扩大了员工人数和支出以满足不断增长的运营需求和探索新的市场机会，净亏损增加171,634美元；截至2023年12月31日，现金及现金等价物约为250万美元
Mobile-health Network Solutions (NASDAQ:MNDR) ("MaNaDr" or "the Company"), a leading Asia-Pacific telehealth provider, today announced that for the first six months of fiscal 2024 ("H1FY24") ended December 31, 2023, the Company had revenue of approximately $6.6 million, approximately a 120% improvement on revenue of $3.0 million for the same period in fiscal 2023 ("H1FY23").
亚太地区领先的远程医疗提供商移动健康网络解决方案（纳斯达克股票代码：MNDR）（“ManaDR” 或 “公司”）今天宣布，在截至2023年12月31日的2024财年（“24财年上半年”）的前六个月中，该公司的收入约为660万美元，比2023财年（“23年上半年”）的300万美元收入增长了约120％。
Telemedicine consultations on the platform increased by approximately 101% during H1FY24, reaching 731,000 compared to 363,000 during H1FY23. The Company believes that this growth was driven by both increased adoption rates and a larger market share. Coupled with the implementation of a dynamic pricing model which increased the average consultation fees, the revenue grew by approximately 120% between H1FY23 and H1FY24. Additionally, the Company improved workflow efficiency for medical professionals by introducing enhancements to the native application, allowing them to focus on core clinical tasks.
在 H1FY24 期间，该平台上的远程医疗咨询增加了约101％，达到73.1万次，相比之下，H1FY23 期间为36.3万次。该公司认为，这种增长是由采用率的提高和市场份额的扩大推动的。再加上动态定价模型的实施提高了平均咨询费，H1FY23 和 H1FY24 之间的收入增长了约120％。此外，该公司通过引入对本机应用程序的增强功能，提高了医疗专业人员的工作流程效率，使他们能够专注于核心临床任务。
The Company's gross profit increased by approximately $0.8 million, or 218% to $1.2 million during H1FY24, mainly due to the 120% increase in revenue and the increase in gross profit margin from 12.7% during H1FY23 to 18.2% during H1FY24.
在 H1FY24 期间，该公司的毛利增长了约80万美元，增长了218％，达到120万美元，这主要是由于收入增长了120％，毛利率从H1FY23 的12.7％提高到H1FY24 期间的18.2％。
The Company expanded its headcount and expenses to meet increased operational demand and explore new market opportunities, resulting in an increase in net loss of $171,634 during H1FY24 as compared to H1FY23.
该公司扩大了员工人数和开支，以满足不断增长的运营需求和探索新的市场机会，与 H1FY23 相比，H1FY24 期间的净亏损增加了171,634美元。
Cash and cash equivalents at December 31, 2023, and June 30, 2023, was approximately $2.5 million and $2.2 million, respectively.
截至2023年12月31日和2023年6月30日，现金和现金等价物分别约为250万美元和220万美元。